Vimarsana
Biggest News Aggregation in the World

Page 11 - Human Use News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Human Use. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Human Use Today - Breaking & Trending Today

Novo Nordisk's Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review - Novo Nordisk (NYSE:NVO) - Vimarsana News

Novo Nordisk's Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review - Novo Nordisk (NYSE:NVO)

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will review Novo Nordisk's application for once-weekly insulin icodec on May 24. Concerns include an increased risk of hypoglycemia in type 1 diabetes patients.

Royalty Pharma and Cytokinetics Announce Expanded Strategic - Vimarsana News

Royalty Pharma and Cytokinetics Announce Expanded Strategic

Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO,...

FDA Promotes Clinical Trial Innovation - Vimarsana News

FDA Promotes Clinical Trial Innovation

As the U.S. Food and Drug Administration observes Clinical Trials Day, we reflect on the progress made and the widespread efforts underway to advance clinical trial innovation.

Source: fda.gov
Idorsia Pharmaceuticals Ltd: Idorsia announces financial results for the first quarter 2024 - advancing the company with renewed vigor - Vimarsana News

Idorsia Pharmaceuticals Ltd: Idorsia announces financial results for the first quarter 2024 - advancing the company with renewed vigor

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2024. Business highlights Viatris

PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation - Vimarsana News

PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation

- European Commission decides against adoption of negative opinion - - Translarna authorization remains active in Europe - - 2024 revenue guidance paused - WARREN, N.J., May 20, 2024 /PRNewswire/ --...